Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

170.81
+2.651.58%
Post-market: 170.820.0100+0.01%16:10 EDT
Volume:6.99M
Turnover:1.19B
Market Cap:44.07B
PE:-12.01
High:171.04
Open:167.73
Low:167.52
Close:168.16
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:0.84
T/O Rate:2.71%
Dividend:2.45
Dividend Rate:1.43%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.28
PE(LYR):-12.01

Loading ...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Artiva Biotherapeutics, Inc. (ARTV)

TIPRANKS
·
Oct 02

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

MT Newswires Live
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Health Insurers Fall After UnitedHealthcare, Aetna Announce 2027 Plan Designs

Reuters
·
Oct 02

Health Care Roundup: Market Talk

Dow Jones
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Offer Insights on Healthcare Companies: Zentek (OtherZTEKF) and Dr Reddy’s Laboratories (RDY)

TIPRANKS
·
Oct 01

National Healthcare Properties Making Progress to Increase SHOP Mix, RBC Capital Markets Says

MT Newswires Live
·
Oct 01

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX) and Compugen (CGEN)

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Definitive Healthcare joins Network Advertising Initiative

TIPRANKS
·
Oct 01

Omega Healthcare Announces New CEO and Board Transition

TIPRANKS
·
Oct 01

Health Care Select Sector SPDR: Pivot points

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Oct 01

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01

3 Australian AI Healthcare Stocks With Revenue Growth Up To 49%

Simply Wall St.
·
Oct 01